H. Moutsopoulos
Annals of the Rheumatic Diseases, 2020
We present a 70-year-old woman who was diagnosed 5 years ago with cryopyrin-associated periodic syndrome on the basis of her clinical picture (episodes of fever, urticarial and maculopapular rash, myalgia, arthralgia and/or arthritis, especially after cold exposure), and genetic testing which confirmed an NLRP3 missense mutation. Since then she has been treated with anti-interleukin-1 subcutaneous therapy (initially on anakinra daily and subsequently on canakinumab 150 mg every 8 weeks). This treatment resulted in complete resolution of disease signs and symptoms. On 15 March 2020 she received her last canakinumab injection. Ten days later she experienced low-grade fever (37.5ºC) and malaise. Her friend, with whom she was exercising, was diagnosed with COVID-19. The following day the patient was tested for SARS-COV-2 and she was found positive. At that time her white cell counts were 4,28x109/L (polymorphonuclear leucocytes 48%, lymphocytes 32%) and serum C-reactive protein was 9 mg/dL (normal value (nv) <5 mg/dL). In a couple of days her symptoms resolved and repeated testing for SARS-COV-2, 12 days later, was negative.
Cited by 11 publications.
Field of study: Medicine